Iranian Red Crescent Medical Journal

Published by: Kowsar

Cloning of the Recombinant Cytochrome P450 Cyp141 Protein of Mycobacterium tuberculosis as a Diagnostic Target and Vaccine Candidate

Mohammad Rabiee-Faradonbeh 1 , 2 , Davood Darban Sarokhalil 3 , Mohammad Mehdi Feizabadi 4 , Amirhooshang Alvandi 4 , Hasan Momtaz 2 , Neda Soleimani 6 and Abolfazl Gholipour 1 , *
Authors Information
1 Department of Microbiology and Immunology, Faculty of Medicine, Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, IR Iran
2 Department of Microbiology, Shahrekord Branch, Islamic Azad University, Shahrekord,IR Iran
3 Department of Microbiology and Immunology, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, IR Iran
4 Department of Microbiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
6 Department of Pathology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: November 01, 2014, 16 (11); e18001
  • Published Online: October 5, 2014
  • Article Type: Research Article
  • Received: February 9, 2014
  • Revised: April 8, 2014
  • Accepted: April 23, 2014
  • DOI: 10.5812/ircmj.18001

To Cite: Rabiee-Faradonbeh M, Darban Sarokhalil D, Feizabadi M M, Alvandi A, Momtaz H, et al. Cloning of the Recombinant Cytochrome P450 Cyp141 Protein of Mycobacterium tuberculosis as a Diagnostic Target and Vaccine Candidate, Iran Red Crescent Med J. 2014 ; 16(11):e18001. doi: 10.5812/ircmj.18001.

Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine. 2007; 25(19): 3742-51[DOI][PubMed]
  • 2. WHO Report Global Tuberculosis Control: Epidemiology, Strategy, Financing. 2012;
  • 3. Neonakis IK, Gitti Z, Krambovitis E, Spandidos DA. Molecular diagnostic tools in mycobacteriology. J Microbiol Methods. 2008; 75(1): 1-11[DOI][PubMed]
  • 4. Smith R. Eradication of tuberculosis by 2050 impossible without new vaccine. BMJ. 2009; 338[DOI][PubMed]
  • 5. Steingart KR, Flores LL, Dendukuri N, Schiller I, Laal S, Ramsay A, et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med. 2011; 8(8)[DOI][PubMed]
  • 6. Al-Attiyah R, Mustafa AS. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect Immun. 2008; 76(9): 4190-8[DOI][PubMed]
  • 7. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995; 346(8986): 1339-45[PubMed]
  • 8. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet. 2010; 375(9731): 2110-9[DOI][PubMed]
  • 9. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999; 284(5419): 1520-3[PubMed]
  • 10. McLean KJ, Dunford AJ, Neeli R, Driscoll MD, Munro AW. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems. Arch Biochem Biophys. 2007; 464(2): 228-40[DOI][PubMed]
  • 11. Darban-Sarokhalil D, Fooladi AA, Bameri Z, Nasiri MJ, Feizabadi MM. Cytochrome CYP141: a new target for direct detection of Mycobacterium tuberculosis from clinical specimens. Acta Microbiol Immunol Hung. 2011; 58(3): 211-7[DOI][PubMed]
  • 12. Mustafa AS. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance. Tuberculosis (Edinb). 2005; 85(5-6): 367-76[DOI][PubMed]
  • 13. Cohen S. Challenges influencing the future of endodontics. New technologies for endodontic education. Aust Endod J. 2001; 27(3): 116-8[PubMed]
  • 14. Chitlaru T, Shafferman A. Proteomic studies of Bacillus anthracis. Future Microbiol. 2009; 4(8): 983-98[DOI][PubMed]
  • 15. Kashino SS, Pollock N, Napolitano DR, Rodrigues V, Jr., Campos-Neto A. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. 2008; 153(1): 56-62[DOI][PubMed]
  • 16. Sumithra TG, Chaturvedi VK, Rai AK, Chougule SS, Rajan LS, Jacob SS, et al. Progress in DNA Vaccinology against Bacterial Diseases–An Update. Adv Anim Vet Sci. 2013; 1(6): 164-77
  • 17. Dominguez J, Gali N, Blanco S, Pedroso P, Prat C, Matas L, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest. 2001; 119(1): 243-9[PubMed]
  • 18. Gholipour A, Moosavian M, Galehdari H, Makvandi M, Memari HR, Alvandi AH. Cloning and periplasmic expression of peptidoglycan-associated lipoprotein (PAL) protein of Legionella pneumophila in Escherichia coli. Jundishapur J Microbiol. 2010; 3(1): 1-9
  • 19. Gholipour A, Moosavian M, Makvandi M, Galehdari H, Alvandi A, Mard SA. Development of an indirect sandwich ELISA for detection of urinary antigen, using Legionella pneumophila PAL protein. World J Microbiol Biotechnol. 2014; 30(5): 1463-71[DOI][PubMed]
  • 20. Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am. 2010; 24(3): 751-68[DOI][PubMed]
  • 21. van Helden PD, Hoal EG. A new TB vaccine: fact or fiction? Comp Immunol Microbiol Infect Dis. 2013; 36(3): 287-94[DOI][PubMed]
  • 22. Jassal MS, Bishai WR. Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis. 2010; 50 Suppl 3-64[DOI][PubMed]
  • 23. Martin Montanes C, Gicquel B. New tuberculosis vaccines. Enferm Infecc Microbiol Clin. 2011; 29: 57-62[DOI]
  • 24. Piubelli L, Campa M, Temporini C, Binda E, Mangione F, Amicosante M, et al. Optimizing Escherichia coli as a protein expression platform to produce Mycobacterium tuberculosis immunogenic proteins. Microb Cell Fact. 2013; 12: 115[DOI][PubMed]
  • 25. Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. Infect Immun. 2001; 69(4): 2714-7[DOI][PubMed]
  • 26. Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol. 2010; 17(5): 793-801[DOI][PubMed]
  • 27. Lu J, Wang C, Zhou Z, Zhang Y, Cao T, Shi C, et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin Dev Immunol. 2011; 2011: 617892[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments